

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Innate and Non-Classical Immune Cells in Cancer Immunotherapy (C5)

March 24-28, 2019 • Keystone Resort • Keystone, Colorado, USA

Scientific Organizers: Nicholas D. Huntington, Eric Vivier, Caroline Robert and Lewis L. Lanier

Supported by the Directors' Fund

Abstract & Scholarship Deadline: November 27, 2018 / Abstract Deadline: December 13, 2018 / Discounted Registration Deadline: January 23, 2019

SUNDAY, MARCH 24

Arrival and Registration

MONDAY, MARCH 25

Welcome and Keynote Address

Ronald Levy, Stanford University, USA
The Immune Response to Cancer

Clinical and Industry Advances in Cancer Immunotherapy

Caroline Robert, Institute Gustave Roussy, France
Advances in Melanoma Immunotherapy

Axel Hoos, GlaxoSmithKline, USA
Innate Immunotherapy Strategies in the Greater Immuno-Oncology Landscape

Stephan Vagner, Institut Curie, France
Translational Control of Immune Checkpoint and Consequences for Cancer Immunotherapy

Short Talk(s) Chosen from Abstracts

Workshop 1: Recent Advances in Drugging the Innate Immune Response

Short Talks Chosen from Abstracts

Myeloid Cells

Lisa M. Coussens, Oregon Health & Science University, USA
Myeloid Suppression of Tumor Immunity

Dmitry I. Gabrilovich, Wistar Institute, USA
Myeloid Derived Suppressor Cells

Miriam Merad, Mount Sinai School of Medicine, USA
DC's in Tumor Immunology

Short Talk Chosen from Abstracts

Poster Session 1

TUESDAY, MARCH 26

NK Cells and ILCs

Eric Vivier, Centre d'Immunologie de Marseille-Luminy / Innate Pharma, France
Inhibitory NK Cells Receptors in Cancer Prognosis and Therapeutic Intervention

Xiaokui Zhang, Celularity Inc., USA
Adoptive NK Cell Therapies

David H. Raulet, University of California, Berkeley, USA
Activation and Inhibition of NK Cells in the Tumor Microenvironment, and Applications to Therapy

Lewis L. Lanier, University of California, San Francisco, USA
NK Cell Memory to Cancer

Short Talk(s) Chosen from Abstracts

Tumor Microenvironment

Maria S. Soengas, Spanish National Cancer Research Centre, Spain
Talk Title to be Announced

Irene M. Ghobrial, Dana-Farber Cancer Institute, USA
Targeting the Tumor Microenvironment in Multiple Myeloma

Ursula Grohmann, University of Perugia, Italy
Tumor Tolerance and IDO

Short Talk Chosen from Abstracts

Poster Session 2

WEDNESDAY, MARCH 27

Innate Checkpoints

Carla V. Rothlin, Yale University, USA
Innate Immune Checkpoints in Cancer

Nicholas D. Huntington, Walter and Eliza Hall Institute, WEHI, Australia
Cytokine Signaling Checkpoints in Cancer Immunity

Alberto Mantovani, Humanitas University, Italy
Checkpoints in DC-NK Cell Tumor Immunity

Michel Sadelain†, Memorial Sloan Kettering Cancer Center, USA
Gene Therapy in Cancer Immunotherapy

Short Talk(s) Chosen from Abstracts

Immune Evasion and Metastasis

Kai W. Wucherpennig, Dana-Farber Cancer Institute, USA
Targeting the Tumor Microenvironment

Ilaria Malanchi, Francis Crick Institute, UK
Neutrophils in the Metastatic Niche

Sohail F. Tavazoie, Rockefeller University, USA
Metastatic Progression as a Model for Understanding Anti-Tumor Immunity

Short Talk Chosen from Abstracts

Poster Session 3

THURSDAY, MARCH 28

ADCC and Phagocytosis

Sergio A. Quezada, University College London, UK
Impact of Fc/FcR Interaction on the Activity of Immune Modulatory Antibodies

Martin J. Glennie, University of Southampton, UK
Developing Immunostimulatory Antibody for the Treatment of Cancer

Andre Veillette, Institut de Recherches Cliniques de Montreal, Canada
Receptors Controlling Phagocytosis in Macrophages

Irving L. Weissman, Stanford University, USA
CD47 in Tumor Immunity

Short Talk(s) Chosen from Abstracts

Workshop 2

Short Talks Chosen from Abstracts

Emerging Techniques in Immunotherapy

Speaker to be Announced

Darrell J. Irvine, Massachusetts Institute of Technology, USA
Safer Delivery of Cancer Immunotherapy Drugs

Thomas Gebhardt, Doherty Institute for Infection and Immunity, Australia
Imaging Melanoma Immune Homeostasis in the Skin

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Innate and Non-Classical Immune Cells in Cancer Immunotherapy (C5)

March 24-28, 2019 • Keystone Resort • Keystone, Colorado, USA

Scientific Organizers: Nicholas D. Huntington, Eric Vivier, Caroline Robert and Lewis L. Lanier

Supported by the Directors' Fund

Abstract & Scholarship Deadline: November 27, 2018 / Abstract Deadline: December 13, 2018 / Discounted Registration Deadline: January 23, 2019

Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Innate and Non-Classical Immune Cells in Cancer Immunotherapy (C5)

March 24-28, 2019 • Keystone Resort • Keystone, Colorado, USA

Scientific Organizers: Nicholas D. Huntington, Eric Vivier, Caroline Robert and Lewis L. Lanier

Supported by the Directors' Fund

Abstract & Scholarship Deadline: November 27, 2018 / Abstract Deadline: December 13, 2018 / Discounted Registration Deadline: January 23, 2019

FRIDAY, MARCH 29

Departure